Fimasartan/Amlodipine

DRUG4 trials

Sponsors

Boryung Pharmaceutical Co., Ltd

Conditions

DyslipidemiaEssential HypertensionHyperlipidemiaHypertension

Phase 1

A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin

CompletedNCT02569814

Boryung Pharmaceutical Co., LtdHyperlipidemia, Hypertension

Start: 2015-09-30End: 2015-12-31Updated: 2016-02-24

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male Subjects

CompletedNCT02920047

Boryung Pharmaceutical Co., LtdHypertension

Start: 2016-10-31End: 2017-01-31Updated: 2018-01-09

Phase 3

Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia

CompletedNCT03156842

Boryung Pharmaceutical Co., LtdDyslipidemia, Essential Hypertension

Start: 2017-05-29End: 2018-12-07Updated: 2019-06-10

BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination

CompletedNCT03991442

Boryung Pharmaceutical Co., LtdEssential Hypertension

Start: 2019-06-17End: 2021-03-02Updated: 2021-07-30

Related Papers

A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy.

2022-12-011 citations